Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 5603-5618

  Pan, Li ^a,b   Zhang, Zhongwang ^a,b   Lv, Jianliang ^a,b   Zhou, Peng ^a,b   Hu, Wenfa ^a,b   Fang, Yuzhen ^a,b   Chen, Haotai ^a,b   Liu, Xinsheng ^a,b   Shao, Junjun ^a,b   Zhao, Furong ^a,b   Ding, Yaozhong ^a,b   Lin, Tong ^a,b   Chang, Huiyun ^a,b   Zhang, Jie ^a,b   Zhang, Yongguang ^a,b   Wang, Yonglu ^a,b  

^a State Key Laboratory of Veterinary Etiological Biology National Foot and Mouth Disease Reference Laboratory Lanzhou Veterinary Research Institute Chinese Academy of A Agricultural Sciences (CAASCAAS)   (China)

^b YANGZHOU UNIVERSITY   (China)

Author keywords

Chitosan; FMDV; Nanoparticles; PLGA; Poly(lactic co glycolic acid); Trehalose

Indexed keywords

CONCANAVALIN A; DNA; FOOT AND MOUTH DISEASE VACCINE; IMMUNOGLOBULIN G; NANOCARRIER; NANOPARTICLE; POLYGLACTIN; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIGEN; VIRUS RNA; CHITOSAN; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TREHALOSE; VIRUS ANTIBODY; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CATTLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOT AND MOUTH DISEASE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MUCOSAL IMMUNITY; NONHUMAN; NOSE SMEAR; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SEROLOGY; SPLEEN CELL; SYMPTOMATOLOGY; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS EXCRETION; ANIMAL; BOVINE; CHEMISTRY; FOOT AND MOUTH DISEASE VIRUS; FOOT-AND-MOUTH DISEASE; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; T LYMPHOCYTE;

BOS; FOOT-AND-MOUTH DISEASE VIRUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CATTLE; CELL PROLIFERATION; CHITOSAN; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID; T-LYMPHOCYTES; TREHALOSE; VIRAL VACCINES;

EID: 84914674794     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S72318     Document Type: Article

References (57)

1. Bachrach HL. Foot-and-mouth disease and its antigens. In: Atassi MZ, Bachrach HL, editors. Immunobiology of Proteins and Peptides-III. New York, NY: Plenum Press; 1985:27–46.
2. Rodriguez LL, Grubman MJ. Foot and mouth disease virus vaccines. Vaccine. 2009;27 Suppl 4:D90–D94.
3. Cox SJ, Parida S, Voyce C, et al. Further evaluation of higher potency vaccines for early protection of cattle against FMDV direct contact challenge. Vaccine. 2007;25(44):7687–7695.
4. Grubman MJ, Baxt B. Foot and mouth disease. Clin Microbiol Rev. 2004;17(2):465–493.
5. Segundo FD, Weiss M, Pérez-Martín E, Dias CC, Grubman MJ, Santos Tde L. Inoculation of swine with foot-and-mouth disease SAP-mutant virus induces early protection against disease. J Virol. 2012;86(3): 1316–1327.
6. Grubman MJ. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals. 2005;33(4): 227–234.
7. Cunliffe HR. Observations on the duration of immunity in cattle after experimental infection with foot-and-mouth disease virus. Cornell Vet. 1964;54:501–510.
8. Doel TR. Optimisation of the immune response to foot-and-mouth disease vaccines. Vaccine. 1999;17(13–14):1767–1771.
9. Zanvit P, Havlícková M, Tácner J, et al. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant. Immunol Lett. 2008;115(2):144–152.
10. Neutra MR. M cells in antigen sampling in mucosal tissues. Curr Top Microbiol Immunol. 1999;236:17–32.
11. Krishnakumar D, Kalaiyarasi D, Bose JC, Jaganathan KS. Evaluation of mucoadhesive nanoparticle based nasal vaccine. Journal of Pharmaceutical Investigation. 2012;42:315–326.
12. Singleton R, Etchart N, Hou S, Hyland L. Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol. 2003;77(21):11303–11311.
13. Liang B, Hyland L, Hou S. Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J Virol. 2001;75(11):5416–5420.
14. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999;178(1):55–65.
15. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57(11):1640–1665.
16. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009;61(2):140–157.
17. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin Immunol. 2000;12(3):163–171; discussion 257–344.
18. Stano A, Nembrini C, Swartz MA, Hubbell JA, Simeoni E. Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. Vaccine. 2012;30(52):7541–7546.
19. Pérez C, Castellanos IJ, Costantino HR, Al-Azzam W, Griebenow K. Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J Pharm Pharmacol. 2002;54(3): 301–313.
20. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine. 2006;24(19): 4201–4211.
21. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001;50(1–2):81–106.
22. Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25(10):1159–1164.
23. Hu Y, Litwin T, Nagaraja AR, et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 2007;7(10):3056–3064.
24. Knipe T, Rieder E, Baxt B, Ward G, Mason PW. Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. J Virol. 1997;71(4):2851–2856.
25. Doel TR, Chong WK. Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus. Arch Virol. 1982;73(2): 185–191.
26. Wang G, Pan L, Zhang Y. Approaches to improved targeting of DNA vaccines. Hum Vaccin. 2011;7(12):1271–1281.
27. Bordelon H, Biris AS, Sabliov CM, Monroe WT. Characterization of plasmid DNA location within chitosan/PLGA/pDNA nanoparticle complexes designed for gene delivery. J Nanomater [serial on the Internet]. 2011;2011:952060 [about 9 pages]. Available from:http://dx.doi.org/10.1155/2011/952060. Accessed October 19, 2014.
28. Vila A, Sánchez A, Pérez C, Alonso MJ. PLA-PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA. Polym Adv Technol. 2002;13(10–12):851–858.
29. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3(3):173–183.
30. Slütter B, Bal S, Keijzer C, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine. 2010;28(38):6282–6291.
31. Xu J, Dai W, Wang Z, Chen B, Li Z, Fan X. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin Vaccine Immunol. 2011;18(1):75–81.
32. Wang G, Pan L, Zhang Y, et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One. 2011;6(11): e27605.
33. Garmise RJ, Staats HF, Hickey AJ. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS Pharm Sci Tech. 2007;8(4):E81.
34. Huang J, Garmise RJ, Crowder TM, et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine. 2004;23(6):794–801.
35. Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25(10):1771–1777.
36. Rweyemamu MM, Black L, Boge A, Thorne AC, Terry GM. The relationship between the 140S antigen dose in aqueous foot-and-mouth disease vaccines and the serum antibody response of cattle. J Biol Stand. 1984;12(1): 111–120.
37. Garmise RJ, Mar K, Crowder TM, et al. Formulation of a dry powder influenza vaccine for nasal delivery. AAPS Pharm Sci Tech. 2006;7(1): E19.
38. Hamblin C, Barnett IT, Hedger RS. A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. I. Development and method of ELISA. J Immunol Methods. 1986;93(1):115–121.
39. Parida S, Anderson J, Cox SJ, Barnett PV, Paton DJ. Secretory IgA as an indicator of oro-pharyngeal foot-and-mouth disease virus replication and as a tool for post vaccination surveillance. Vaccine. 2006;24(8): 1107–1116.
40. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171(1):131–137.
41. Reid SM, Ebert K, Bachanek-Bankowska K, et al. Performance of real-time reverse transcription polymerase chain reaction for the detection of foot-and-mouth disease virus during field outbreaks in the United Kingdom in 2007. J Vet Diagn Invest. 2009;21(3):321–330.
42. Bao HF, Li D, Guo JH, et al. A highly sensitive and specific multiplex RT-PCR to detect foot-and-mouth disease virus in tissue and food samples. Arch Virol. 2008;153(1):205–209.
43. Alexandersen S, Mowat N. Foot-and-mouth disease: host range and pathogenesis. Curr Top Microbiol Immunol. 2005;288:9–42.
44. Korn G. Experimentelle untersuchungen zum virusnachweis im inkubationsstadium der maulund klauenseuche und zu ihrer pathogneses. Arch Exp Veterinarmed. 1957;11:637–649. German.
45. Sutmoller P, McVicar JW. Pathogenesis of foot-and-mouth disease: the lung as an additional portal of entry of the virus. J Hyg (Lond). 1976; 77(2):235–243.
46. Arzt J, Pacheco JM, Rodriguez LL. The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation. Identification of the nasopharynx as the primary site of infection. Vet Pathol. 2010;47(6): 1048–1063.
47. Pacheco JM, Arzt J, Rodriguez LL. Early events in the pathogenesis of foot-and-mouth disease in cattle after controlled aerosol exposure. Vet J. 2010;183(1):46–53.
48. Pay TW, Hingley PJ. Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine. 1987;5(1): 60–64.
49. Golde WT, Pacheco JM, Duque H, et al. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response. Vaccine. 2005;23(50):5775–5782.
50. Salt JS, Barnett PV, Dani P, Williams L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine. 1998;16(7):746–754.
51. Barnett PV, Cox SJ, Aggarwal N, Gerber H, McCullough KC. Further studies on the early protective responses of pigs following immunization with high potency foot and mouth disease vaccine. Vaccine. 2002; 20(25–26):3197–3208.
52. Lewis SA, Morgan DO, Grubman MJ. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol. 1991;65(12):6572–6580.
53. Rowlands DJ, Sangar DV, Brown F. A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol. 1975;26(3):227–238.
54. Chinsangaram J, Beard C, Mason PW, Zellner MK, Ward G, Grubman MJ. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J Virol. 1998;72(5): 4454–4457.
55. Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology. 1999;263(2):496–506.
56. Grubman MJ, Lewis SA, Morgan DO. Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems. Vaccine. 1993;11(8):825–829.
57. Moon HJ, Lee JS, Talactac MR, et al. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet Microbiol. 2012;160(3–4):277–289.